Extended Data Fig. 6: The ABACUS ctDNA study in the neoadjuvant setting supports the association of ctDNA with clinical outcomes.
From: ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
a, ABACUS consort diagram depicting how patients in the ctDNA BEP (n = 40) were identified from the overall ABACUS study population (n = 95). ABACUS is a phase II prospective neoadjuvant ctDNA data from a prospective phase II study of neoadjuvant atezolizumab before cystectomy in muscle invasive urothelial cancer. b. Kaplan–Meier estimates comparing recurrence-free survival (RFS) of ctDNA-positive patients (red) to ctDNA-negative patients (blue) as assessed at the baseline (C1D1) time point before neoadjuvant treatment. c, Kaplan–Meier estimates for ctDNA-positive (red) versus ctDNA-negative patients (blue) at the post-neoadjuvant time point.
